openPR Logo
Press release

New Report By Coherent Market Insights: Zika Vaccines Market

04-24-2018 04:07 PM CET | Health & Medicine

Press release from: Pharmaceutical

New Report By Coherent Market Insights: Zika Vaccines Market

Zika vaccines are developed for immunization & prevention against diseases caused by Zika virus. This virus belongs to genus Flavivirus and is transmitted by Aedes mosquitoes. The virus can also be transmitted through blood transfusion, sexual contact or from infected pregnant women to the fetus. Diagnosis of this infection is confirmed by detecting viral DNA through PCR. However, only 1 in 4 people with zika infection are prone to develop symptoms. In November 2016, the World Health Organization (WHO) declared that zika infection no longer constitutes a Public Health Emergency of International Concern (PHEIC) as major cases of zika virus were asymptomatic.

In April 2015, a major ongoing outbreak of Zika virus was registered in Brazil, which later affected the population in South and Central America. This outbreak caused mild illness (fever, rashes, joint pains, conjunctivitis, nausea, and muscle pain), though the recent outbreaks showed severe complications such as microcephaly, Guillain-Barré syndrome, and various congenital neurological abnormalities in infants who were born to infected mothers. The link between zika virus and microcephaly and Guillain-Barré syndrome was identified and reported in 2015 in Brazil.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/413

According to the Centers for Disease Control and Prevention (CDC), 70 new zika virus infection cases were reported in the U.S. in 2015, which increased to 41,181 cases in 2016. Lack of reporting is a major factor for lower incidence rate in 2015. Increase in awareness can result in more diagnosis and reporting thus generating growth of the global zika vaccines market.

Researchers at the Queensland University of Technology found that the extract of San Francisco plant (Codiaeum variegatum) found in Australia, can kill the zika virus. This extract can arrest the virus and stop it from replicating without causing any damage to the host cells.

Continuous increase in human clinical trials and rise in number of zika cases will drive the growth of Zika vaccines market

As of March 2016, 67 companies and research institutions were working on various kinds of R&D projects and clinical trials aided to develop effective vaccines against zika virus. The FDA approved the first human clinical trial for GLS–5700 in June 2016, a zika vaccine being developed by Inovio Pharmaceuticals. Further in 2017, a grant was approved for phase 2 clinical trials for a DNA vaccine conducted by NIAID’s Vaccine Research Center (VRC).

Increasing awareness among the population would aid in controlling the incidence rate of zika infection. The WHO implemented a global framework for creating public awareness through its Zika Strategic Response Framework and Joint Plan in February 2016. This plan outlines all the points to be taken care of at the time of infections. In June 2016, WHO Regional Office for Europe developed a training curriculum to increase awareness by the publication of Zika Risk Assessment for European Region.

High investment costs required for R&D and the development of effective zika virus vaccines serves as a restraining factor for the global zika vaccines market.

While major of the Zika virus cases occur in tropical regions such as Brazil, Paraguay, Venezuela, Colombia and Suriname, there are higher chances of mosquito infections in tropical areas of the U.S. like Texas and Florida. According to Pan American Health Organization, around 1,246 suspected and confirmed cases were reported between epidemiological week (EW) 10 and EW 14 of 2016 in the sub region which involves Brazil, Argentina, Peru and Ecuador.

Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/413

Competitive Landscape

Some key players operating in the zika vaccines market are Cerus Corporation, Biken Inc, GlaxoSmithKline plc, Bharat Biotech International Pvt. Ltd, GeneOne Life Science, Inovio Pharmaceuticals, Immunovaccine Inc., NewLink Genetics Corp. and Sanofi S.A. The companies launched various R&D measures and clinical trials to attain immunogenicity against zika virus. In February 2016, Sanofi S.A launched a vaccine research and development project, with the introduction of Dengvaxia (Dengue vaccine) that will aid the company understand the Zika virus and develop an effective vaccine against it. Likewise, Inovio Pharmaceuticals initiated a clinical study of zika vaccine (GLS-5700) in Puerto Rico in August 2016. This trial may provide a potential push to Inovio’s vaccine if positive results are reported as there was a rapid progression of zika outbreak in Puerto Rico at that time. This could benefit the trial in assessing true efficacy and safety of the vaccine. Rapid progression in clinical trials and approval would augment the zika vaccines market growth.

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit our news Website: http://www.coherentchronicle.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release New Report By Coherent Market Insights: Zika Vaccines Market here

News-ID: 1028930 • Views:

More Releases from Pharmaceutical

Pharmaceutical Market Report 2018 Companies included CCM Pharmaceuticals, Pharmaniaga, Rosemont Pharmaceuticals, Simpor Pharma, Bosch Pharmaceuticals, NOOR VITAMINS and Others
Pharmaceutical Market Report 2018 Companies included CCM Pharmaceuticals, Pharma …
We have recently published this report and it is available for immediate purchase. For inquiry Email us on: jasonsmith@marketreportscompany.com ********* This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025, etc. The report also provides
Equine Healthcare Market Global Industry Insights, Trends, 2026
Equine Healthcare Market Global Industry Insights, Trends, 2026
Equine Healthcare refers to the activities and practices aimed for the maintenance of horses. Equine healthcare offers the veterinary services intended for treating horses to enhance their quality of life, develop quality animal food and increase lifespan. The total equine population is directly proportional to the quality of equine healthcare. Equine healthcare includes a number of activities including diagnosis, therapies and supplements for maintaining internal health of horses. The
Novel Drug Delivery System (NDDS) Market - Global Industry Insights
Novel Drug Delivery System (NDDS) Market - Global Industry Insights
Novel Drug Delivery System (NDDS) refers to the formulations, systems to transport pharmaceutical compound in the body, and approaches needed to achieve the desired therapeutic effect. The side effects and slow processing of conventional drug therapy are contributing to the emergence of novel drug delivery system’s concept. Novel ideas based on interdisciplinary approaches controlling the pharmacodynamics, immunogenicity, pharmacokinetics, bio-recognition, and efficiency of drugs were generated. This new system helps in
The Global Anti-suicide Drugs Market was valued at US$ 3,318.3 million in 2015 and is projected to expand at a CAGR of 4.2% during the forecast period 2016-2024
The Global Anti-suicide Drugs Market was valued at US$ 3,318.3 million in 2015 a …
The Global Anti-suicide Drugs Market was valued at US$ 3,318.3 million in 2015 and is projected to expand at a CAGR of 4.2% during the forecast period (2016-2024), as highlighted in a new report published by Coherent Market Insights. Introduction of novel approved drugs, expected to be commercialized post-2020, intended for treatment of suicidal ideation would be a major breakthrough for the global anti-suicide drugs market. Until recently, suicidal ideation has

All 5 Releases


More Releases for Zika

Zika Virus Vaccines Market 2022 | High rate of incidence of active Zika virus in …
Zika Virus Vaccines Market Report, published by Allied Market Research, forecasts that the global market is expected to garner $18,697 million by 2022, registering a CAGR of 5.2% during the forecast period 2017-2022.Key opportunities include the need for vaccines for immunization & prevention of further spread of Zika virus infection and for treatment of Zika-linked birth defects. Do Enquiry for Sample Report @ https://www.alliedmarketresearch.com/request-sample/1817 The outbreak of Zika virus infection in Latin
Zika Vaccines Market Size, Share, Development by 2023
New report published by Market Research Report Store (MRRS) which offers insights on the global Zika Vaccines market. Click to view the full report TOC, figure and tables: https://www.marketresearchreportstore.com/reports/212025/global-zika-vaccines-market Global Zika Vaccines Market: Forecast by Type / Application / Region According to this study, over the next five years the Zika Vaccines market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2023, from
Zika Virus Testing Market Opportunity Assessment Research Study
One of the biggest public growing threat is the rapid emergence of mosquito borne virus called as Zika virus. Zika virus was first identified in rhesus monkey in the year 1947 in Uganda. Later in 1952 the virus was identified in humans. The virus is a single-stranded RNA virus of the Flaviviridae family, and is transmitted by two species of Aedes genus, Aedes aegypti and Aedes albopictus. These are the
Global Zika Virus Market Research Report 2017
Qyresearchreports include new market research report "Global Zika Virus Market Research Report 2017" to its huge collection of research reports. The global market for Zika Virus has been marked on several factors that are on the verge or have already impacted the growth of the market in several contexts. The report further pronounces different statistics and data pertaining to the global Zika Virus market. The core aim of the report is
Global Zika Virus Market Research Report 2017
The Global Zika Virus 2017 Market Research Report is a professional and in-depth study on the current state of the Zika Virus industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Zika Virus market analysis is provided for the international market including development history, competitive landscape analysis, and major regions’ development status. Secondly, development policies and plans are discussed as well
Zika Vaccines Market - Global Industry Insights 2025
Zika vaccines are developed for immunization & prevention against diseases caused by Zika virus. This virus belongs to genus Flavivirus and is transmitted by Aedes mosquitoes. The virus can also be transmitted through blood transfusion, sexual contact or from infected pregnant women to the fetus. Diagnosis of this infection is confirmed by detecting viral DNA through PCR. However, only 1 in 4 people with zika infection are prone to develop